When patients ask about longterm risks, be transparent about what is known and unknown
This blood work can help understand the body's ability to heal, and what deficiencies need to be addressed
4.3 Comparative safety profiles of biomaterial and systemic therapeutic approaches Biomaterial delivery platforms can markedly reduce the off-target toxicities of systemic immunotherapies by concentrating antigen or immunomodulatory cargo in tolerogenic tissues or the diseased microenvironment, enabling lower total doses, controlled release, and biomimetic presentation that better recapitulates apoptotic-cell-driven tolerance (206, 207)
A team led by Luba Yammine, a clinician, and researcher at the University of Texas Health Science Center at Houston, found in 2021 that 46% of patients who wore nicotine patches and received weekly injections of exenatide, a first-generation GLP-1 analog, stopped smoking , versus 27% of people who relied only on the patches. Another study with 127 people with alcohol use disorder who were given exenatide, a GLP-1 agonist, displayed less activity in the brains reward centers on fMRI when shown pictures of alcohol
[DOI] [PMC free article] [PubMed] [Google Scholar] 102.Patti M.E., Butte A.J., Crunkhorn S., Cusi K., Berria R., Kashyap S., Miyazaki Y., Kohane I., Costello M., Saccone R., et al
Obesity is recognized as a chronic, relapsing disease, much like hypertension or asthma
